Fracture risk assessment

Displaying 2 studies

  • A Study to Evaluate Zoledronic Acid for Fracture Prevention in Parkinson's Disease Patients Rochester, MN

    The purpose of this study is to evaluate the use of a single infusion of zoledronic acid-5 mg (ZA) vs. placebo for the prevention of fractures in men and women aged 65 years and older with Parkinson's Disease with 2 years of follow-up.

  • A Study to Evaluate Bone Mineral Densities and Serological Markers to Assess Fracture Risk in Children and Young Adults with Bleeding Disorders Rochester, MN

    The primary objectives of this study are to obtain serological bone turnover markers and bone mineral density (BMD) measurements from hemophilia A and von Willebrand disease (VWD) patients aged  ≥ 6 to ≤ 25 years, to compare BMD measurements by HRpQCT and DXA with respect to severity of hemophilia A (mild, moderate, severe) and vWD, annualized bleeding rates, activity and joint scores, and to identify multivariate predictors (correlates) of BMD measurements, including serological bone turnover markers, biochemical and hormonal markers, chronological age, Tanner stage, gender, height, weight, BMI, type of bleeding disorder, severity of bleeding disorder, history of inhibitors, and ...

.

Mayo Clinic Footer